Lexicon Pharmaceuticals
LXRX
103 hedge funds and large institutions have $308M invested in Lexicon Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.43M
2.64% less ownership
Funds ownership: 99.02% → 96.38% (-2.6%)
6% less funds holding
Funds holding: 109 → 103 (-6)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
53% less capital invested
Capital invested by funds: $662M → $308M (-$354M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$7.74M |
| 2 |
Millennium Management
New York
|
+$3.67M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.64M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.51M |
| 5 |
Morgan Stanley
New York
|
+$865K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$18.6M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$9.31M |
| 3 |
ClearBridge Investments
New York
|
-$9.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.65M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.25M |
LXRX Hedge Fund Activity: Q3 2019 in Review
103 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2019, worth a combined $308M — down 53% from $662M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LXRX and 18 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 23 added.
The largest buyer was Boxer Capital, opening a new position worth an estimated $7.74M. The largest seller was First Manhattan, exiting entirely with an estimated $18.6M sold.
- 103 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2019, down from 109 in Q2 2019.
- Funds reported $308M of Lexicon Pharmaceuticals stock for Q3 2019, down 53% quarter-over-quarter.
- 18 funds opened new Lexicon Pharmaceuticals positions in Q3 2019 and 23 closed out, a net change of -5 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2019 was Boxer Capital, an estimated $7.74M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2019 was First Manhattan, an estimated $18.6M sold.
Based on aggregated 13F filings for Q3 2019.